Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

医学 索拉非尼 甲状腺癌 放射性碘 内科学 安慰剂 肿瘤科 双盲 耐火材料(行星科学) 临床试验 碘 核医学 甲状腺 病理 肝细胞癌 冶金 材料科学 替代医学 物理 天体生物学
作者
Marcia S. Brose,Christopher M. Nutting,Barbara Jarząb,Rossella Elisei,Salvatore Siena,Lars Bastholt,Christelle de la Fouchardière,Furio Pacini,Ralf Paschke,Young Kee Shong,Steven I. Sherman,Johannes W. A. Smit,John Chung,Christian Kappeler,Carol Peña,István Molnár,Martin Jean Schlumberger
出处
期刊:The Lancet [Elsevier BV]
卷期号:384 (9940): 319-328 被引量:1672
标识
DOI:10.1016/s0140-6736(14)60421-9
摘要

Patients with radioactive iodine ((131)I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis because of the absence of effective treatment options. In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment of patients with this type of cancer.In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (DECISION), we investigated sorafenib (400 mg orally twice daily) in patients with radioactive iodine-refractory locally advanced or metastatic differentiated thyroid cancer that had progressed within the past 14 months. Adult patients (≥18 years of age) with this type of cancer were enrolled from 77 centres in 18 countries. To be eligible for inclusion, participants had to have at least one measurable lesion by CT or MRI according to Response Evaluation Criteria In Solid Tumors (RECIST); Eastern Cooperative Oncology Group performance status 0-2; adequate bone marrow, liver, and renal function; and serum thyroid-stimulating hormone concentration lower than 0·5 mIU/L. An interactive voice response system was used to randomly allocate participants in a 1:1 ratio to either sorafenib or matching placebo. Patients, investigators, and the study sponsor were masked to treatment assignment. The primary endpoint was progression-free survival, assessed every 8 weeks by central independent review. Analysis was by intention to treat. Patients in the placebo group could cross over to open-label sorafenib upon disease progression. Archival tumour tissue was examined for BRAF and RAS mutations, and serum thyroglobulin was measured at baseline and at each visit. This study is registered with ClinicalTrials.gov, number NCT00984282, and with the EU Clinical Trials Register, number EudraCT 2009-012007-25.Patients were randomly allocated on a 1:1 basis to sorafenib or placebo. The intention-to-treat population comprised 417 patients (207 in the sorafenib group and 210 in the placebo group) and the safety population was 416 patients (207 in the sorafenib group and 209 in the placebo group). Median progression-free survival was significantly longer in the sorafenib group (10·8 months) than in the placebo group (5·8 months; hazard ratio [HR] 0·59, 95% CI 0·45-0·76; p<0·0001). Progression-free survival improved in all prespecified clinical and genetic biomarker subgroups, irrespective of mutation status. Adverse events occurred in 204 of 207 (98·6%) patients receiving sorafenib during the double-blind period and in 183 of 209 (87·6%) patients receiving placebo. Most adverse events were grade 1 or 2. The most frequent treatment-emergent adverse events in the sorafenib group were hand-foot skin reaction (76·3%), diarrhoea (68·6%), alopecia (67·1%), and rash or desquamation (50·2%).Sorafenib significantly improved progression-free survival compared with placebo in patients with progressive radioactive iodine-refractory differentiated thyroid cancer. Adverse events were consistent with the known safety profile of sorafenib. These results suggest that sorafenib is a new treatment option for patients with progressive radioactive iodine-refractory differentiated thyroid cancer.Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals (an Amgen subsidiary).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LZY完成签到,获得积分10
1秒前
CAO完成签到,获得积分10
1秒前
香蕉觅云的应助被梁三柏采纳,获得10
1秒前
3秒前
3秒前
3秒前
哎呦喂完成签到,获得积分10
4秒前
科研通AI6.3的应助被炸薯条采纳,获得10
4秒前
华仔的应助被风继续吹采纳,获得10
4秒前
冰棍完成签到,获得积分10
6秒前
6秒前
6秒前
丑角苏发布了新的文献求助10
6秒前
6秒前
CipherSage的应助被亚米采纳,获得10
8秒前
8秒前
优美元枫发布了新的文献求助10
8秒前
蛋包洋芋发布了新的文献求助10
8秒前
我是谁的应助被永毅采纳,获得50
9秒前
黑浩源完成签到,获得积分10
9秒前
10秒前
shuzicaiji完成签到,获得积分10
10秒前
小杨肖恩发布了新的文献求助10
11秒前
11秒前
你很棒发布了新的文献求助30
11秒前
dfj完成签到,获得积分10
13秒前
Ava的应助被小艾同学采纳,获得30
14秒前
小张困困发布了新的文献求助10
15秒前
斯文败类的应助被唐唐采纳,获得10
16秒前
16秒前
17秒前
香蕉觅云的应助被多绚题采纳,获得10
18秒前
梁三柏发布了新的文献求助10
19秒前
19秒前
小吴呀完成签到 ,获得积分10
19秒前
时迁完成签到 ,获得积分10
19秒前
20秒前
Xiaopei完成签到,获得积分10
20秒前
小羊发布了新的文献求助10
22秒前
阿冲发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527